Conference Call with PI Industries Management and Analysts on Q4FY24 Performance and Outlook. Listen to the full earnings transcript.
Agrochemicals company PI Industries announced FY24 results: Overall 18% YoY revenue growth 19% growth in Agchem Exports over a high base mainly on account of scale-up of existing products and introduction of 6 new products. Biologicals products’ revenue increased by ~29% YoY. Overheads increase attributable to the newly acquired Pharma businesses (~16%) and scale-up of Exports (~14%). Overall favorable product mix and operating leverage reflected in improvement in EBITDA margin to 26%. Net profit improved by 37% YoY attributable to EBITDA growth, low ETR. Cash flow from operating activities increased ~16% to Rs 20,359 million (FY23 Rs 17,572 million). Net fixed asset increase by Rs 7,902 million YoY. Total capex for FY24 is Rs 10,823 million including Pharma1 acquired assets of Rs 4,972 million. The capex excluding this addition is Rs 5,851 million (FY23 Rs 3,385 million). Trade working capital in terms of Days of Sales improved to 59 days as on 31- March-24 vs. 79 days as on 31-March-23. Inventory levels of Rs 13,012 million, reduced in terms of Days of Sales from 79 days as on 31-March-23 to 62 days. Free Cash flow increased 20% to Rs 14,152 million (FY23 Rs 11,750 million). Surplus cash net of debt is Rs 38,825 million Proforma EBITDA for FY24, before development spend of ~Rs. 460 million, works out to ~12%. Inventory of Rs 862 million reduced from Rs 865 million as on 31-Dec-23. Capex FY24 of Rs 1,322 million Result PDF